H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Neurogene to $49 from $51 and keeps a Buy rating on the shares. The firm expects positive efficacy data for NGN-401 in Q4.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue